Silexion Therapeutics (SLXN) Balance Sheet: Assets & Liabilities

Silexion Therapeutics (SLXN) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Silexion Therapeutics reported total assets of $7.21M and total liabilities of $4.61M. Shareholders' equity was $2.60M. Total debt stood at $468.00K against $5.99M in cash and short-term investments, a net cash position of $5.52M. That puts debt-to-equity at 0.18.

Silexion Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Silexion Therapeutics Corp (SLXN) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2013	FY 2012
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2013	Dec 2012
Current Assets
Cash and Cash Equivalents	5.99	1.19	4.60	8.26	0.04	0.05	0.79	1.60
Cash & Short-Term Investments	5.99	1.19	4.60	8.26	0.04	0.05	0.79	1.60
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.09	0.16
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Other Current Assets	0.65	1.06	0.02	0.04	0.37	0.00	0.01	-
Total Current Assets	6.64	2.25	4.98	8.84	0.41	0.05	0.93	1.79
Non-Current Assets
Property, Plant & Equipment (Net)	0.44	0.56	0.25	0.46	0.00	0.00	0.01	0.01
Long-Term Investments	0.06	0.00	0.00	0.00	115.01	0.00	-	-
Other Non-Current Assets	0.08	0.05	0.03	0.03	0.00	0.08	-	-
Total Non-Current Assets	0.58	0.61	0.28	0.49	115.01	0.08	-	-
Total Assets	7.22	2.86	5.26	9.33	115.41	0.13	0.94	1.80
Current Liabilities
Accounts Payable	0.79	1.72	0.32	0.24	0.00	0.00	0.10	0.08
Short-Term Debt	0.18	1.00	0.11	0.12	0.00	0.00	-	-
Accrued Liabilities	0.86	0.64	1.36	1.00	-	-	0.14	0.09
Other Current Liabilities	1.79	0.00	0.20	0.00	0.35	0.03	-	-
Total Current Liabilities	2.76	3.52	2.20	1.61	0.35	0.03	0.24	0.17
Non-Current Liabilities
Long-Term Debt	0.29	2.96	0.06	0.16	0.00	0.00	-	-
Other Non-Current Liabilities	1.57	0.00	15.06	14.65	0.16	0.27	-	-
Total Non-Current Liabilities	1.85	3.33	15.12	14.80	0.16	0.27	-	-
Total Liabilities	4.61	6.85	17.31	16.41	0.51	0.30	0.24	0.17
Stockholders' Equity
Common Stock	0.04	0.00	0.00	0.00	115.00	0.00	-	-
Retained Earnings	-55.17	-43.25	-26.81	-21.87	-0.95	-0.20	-4.47	-3.11
Additional Paid-in Capital	57.73	39.26	11.34	11.20	0.86	0.03	-	-
Minority Interest	0.00	0.00	3.42	3.59	0.00	0.00	-	-
Shares Outstanding	0.31	0.01	0.01	0.01	-	-	-	-
Total Stockholders' Equity	2.60	-3.99	-15.48	-10.67	114.91	-0.17	0.70	1.63
Total Liabilities & Equity	7.22	2.86	5.26	9.33	115.41	0.13	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Silexion Therapeutics Balance Sheet

How much debt does Silexion Therapeutics have?

Silexion Therapeutics had total debt of $468.00K as of Dec 31, 2025, against $5.99M in cash and short-term investments. Its debt-to-equity ratio was 0.18. Total debt was $3.96M a year earlier.

What are Silexion Therapeutics's total assets?

Silexion Therapeutics reported total assets of $7.21M as of Dec 31, 2025, up 152.0% from $2.86M a year earlier. Total liabilities were $4.61M.

What is Silexion Therapeutics's shareholders' equity?

Silexion Therapeutics's shareholders' equity was $2.60M as of Dec 31, 2025, or about $8.33 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition